Okyo Pharma (OKYO) Fundamental Analysis: Revenue, Earnings & Valuation

9.57 / 10

Outperform

Fundamental analysis rates OKYO as Outperform with a 9.6/10 quality score. Strong points include a high interest coverage ratio (35.1) and favorable Revenue‑MV and Asset‑MV metrics. However, revenue growth rates are extremely high yet historically linked to negative returns, indicating volatility risk.

Analysis Checks(6/10)

Revenue-MV

Value-0.28

Score3/3

Weight68.99%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score0/3

Weight-29.68%

1M Return-4.79%

Inventory turnover ratio

Value103.94

Score2/3

Weight-7.87%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value100.00

Score0/3

Weight-29.15%

1M Return-4.96%

PB-ROE

Value15.13

Score0/3

Weight23.24%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value6.39

Score2/3

Weight-2.44%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-8.00%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score0/3

Weight-28.67%

1M Return-4.63%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-7.56%

1M Return-1.13%

Asset-MV

Value-0.49

Score3/3

Weight121.13%

1M Return11.61%

Is OKYO undervalued or overvalued?

OKYO scores 9.57/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, 0.00% net margin, -18.31 P/E ratio, -24.74 P/B ratio, and 50.00% earnings growth, these metrics solidify its Outperform investment rating.